OT mobile menu



Approval Just in Time for Lung Cancer Awareness Month

The US Food and Drug Administration has granted accelerated approval for Merck’s anti-PD-1 agent Keytruda for treating patients with refractory metastatic non-small cell lung cancer.

Recent Content

Gut bacteria improve antitumor immunity and the efficacy of antitumor immune checkpoint-blockade therapy, according to a pair of recently published studies..

Genetic mutation analysis confirms the malignant potential of intermediate skin lesions that are neither benign moles nor yet melanomas.

A 47-year-old woman undergoes a hysterectomy and a section of the endometrium is sent for analysis. What is your diagnosis?

Research scientists have developed a test that may be able to aid in the diagnosis of ovarian cancer at an early stage.

Pembrolizumab (Keytruda), a PD-1 or “checkpoint” inhibitor, is showing promise against metastatic renal cell carcinoma (RCC) and now is being tested in a phase II trial to determine what effects it may have when combined with bevacizumab (Avastin) in patients with metastatic kidney cancer.

A 56-year-old man presents with an enlarged prostate. After a biopsy is performed, what is your diagnosis?

New studies are suggesting that there are novel associations between gene mutations and immune surveillance that could impact the response to immunotherapy in patients with lung cancer.

By clicking Accept, you agree to become a member of the UBM Medica Community.